{"id":"and017","safety":{"commonSideEffects":[{"rate":"null","effect":"Increased risk of diabetic ketoacidosis"},{"rate":"null","effect":"Increased risk of genital yeast infections"},{"rate":"null","effect":"Increased risk of hypotension"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"AND017 works by inhibiting the SGLT2 receptor, which reduces glucose reabsorption in the kidneys and lowers blood glucose levels. This mechanism is similar to other SGLT2 inhibitors, such as canagliflozin and empagliflozin.","oneSentence":"AND017 is a small molecule that targets the SGLT2 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:42:34.771Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"},{"name":"Heart failure"}]},"trialDetails":[{"nctId":"NCT07494409","phase":"PHASE3","title":"A Study of AND017 to Evaluate Efficacy and Safety in Dialysis-Dependent Chronic Kidney Disease (DD-CKD) Patients With Anemia","status":"RECRUITING","sponsor":"Kind Pharmaceuticals LLC","startDate":"2025-10-31","conditions":"Anemia Due to Chronic Kidney Disease","enrollment":300},{"nctId":"NCT07487727","phase":"PHASE3","title":"A Study of AND017 to Evaluate Efficacy and Safety in Patients With Anemia Due to Non-Dialysis-Dependent Chronic Kidney Disease (NDD-CKD)","status":"RECRUITING","sponsor":"Kind Pharmaceuticals LLC","startDate":"2025-12-03","conditions":"Anemia Due to Chronic Kidney Disease","enrollment":240},{"nctId":"NCT06075030","phase":"PHASE2","title":"A Study of AND017 in Cancer Related Anemic Patients Receiving Chemotherapy","status":"NOT_YET_RECRUITING","sponsor":"Kind Pharmaceuticals LLC","startDate":"2027-12","conditions":"Chemotherapy Induced Anemia","enrollment":36},{"nctId":"NCT06302491","phase":"PHASE2","title":"A Study of Safety and Efficiency of AND017 in Patients With β-thalassemia","status":"RECRUITING","sponsor":"Kind Pharmaceuticals LLC","startDate":"2024-05-27","conditions":"β -Thalassemia","enrollment":64},{"nctId":"NCT06304103","phase":"PHASE2","title":"A Study of Efficacy and Safety of AND017 in Patients With Myelodysplastic Syndrome","status":"RECRUITING","sponsor":"Kind Pharmaceuticals LLC","startDate":"2025-03-14","conditions":"Myelodysplastic Syndromes","enrollment":63},{"nctId":"NCT06075043","phase":"PHASE2","title":"A Study of AND017 to Treat Cancer Related Anemia in Patients Not Receiving Chemotherapy","status":"NOT_YET_RECRUITING","sponsor":"Kind Pharmaceuticals LLC","startDate":"2027-12","conditions":"Cancer-Related Anemia","enrollment":36},{"nctId":"NCT05265325","phase":"PHASE2","title":"A Study of AND017 to Treat Anemia in Chronic Kidney Disease Patients on Dialysis","status":"COMPLETED","sponsor":"Kind Pharmaceuticals LLC","startDate":"2023-05-03","conditions":"Renal Anemia","enrollment":175},{"nctId":"NCT05035641","phase":"PHASE2","title":"A Study of AND017 to Treat Anemia in Non-dialysis-Dependent Chronic Kidney Disease (NDD-CKD) Patients","status":"COMPLETED","sponsor":"Kind Pharmaceuticals LLC","startDate":"2021-10-18","conditions":"Renal Anemia","enrollment":113},{"nctId":"NCT04712500","phase":"PHASE1","title":"A Food-Effect Study of AND017 in Healthy Participants","status":"COMPLETED","sponsor":"Kind Pharmaceuticals LLC","startDate":"2020-07-30","conditions":"Healthy Volunteers","enrollment":14},{"nctId":"NCT04751539","phase":"PHASE1","title":"A Dose-escalation Study of AND017 in Healthy Subjects","status":"COMPLETED","sponsor":"Kind Pharmaceuticals LLC","startDate":"2018-07-16","conditions":"Healthy Volunteers","enrollment":78}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"AND017","genericName":"AND017","companyName":"Kind Pharmaceuticals LLC","companyId":"kind-pharmaceuticals-llc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AND017 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes, Heart failure.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":3,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}